NCT03831932 2026-04-13Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung CancerNational Cancer Institute (NCI)Phase 1/2 Active not recruiting22 enrolled 12 charts